Multi center observational study of resistance mechanisms to alectinib in patients with ALK-rearranged, unresectable, locally advanced or metastatic non-small cell lung cancer
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000038934
- Lead Sponsor
- Japanese Foundation for Cancer Research / CHUGAI PHARMACEUTICAL CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Patients who are judged by physician in charge of a case to be inappropriate to participate in study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To explore the resistance mechanisms to alectinib and relationship between the resistance mechanisms and efficacy of first-line alectinib and second-line therapy
- Secondary Outcome Measures
Name Time Method To establish the patient derived cancer cell line and analyze the resistance mechanisms besides secondary mutations in ALK, and to analyze the immune microenvironment in ALK rearranged cancer